Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.

Details

Language :

English

ISSN :

03618609

Volume :

99

Issue :

2

Database :

Complementary Index

Journal :

American Journal of Hematology

Publication Type :

Academic Journal

Accession number :

174913627

Full Text :

https://doi.org/10.1002/ajh.27161